MX2017002328A - Analogos de dioxolano de uridina para el tratamiento del cancer. - Google Patents
Analogos de dioxolano de uridina para el tratamiento del cancer.Info
- Publication number
- MX2017002328A MX2017002328A MX2017002328A MX2017002328A MX2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- uridine
- alkyl
- dioxolane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): en donde: R1 es OR11 o NR5R5', R2 es H o F; R5 es H, alquilo C1-C6, OH, C(=O)R6, O(C=O)R6 o O(C=O)OR6; R5' es H o alquilo C1-C6; R6 es alquilo C1-C6 o cicloalquilo C3-C7; R13 es H, fenilo, piridilo, bencilo, indolilo o naftilo, en donde el fenilo, piridilo, bencilo, indolilo y naftilo es opcionalmente sustituido con 1, 2 o 3 R22 y las otras variables son como se define en las reivindicaciones, que se utilizan en el tratamiento del cáncer y aspectos relacionados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 | ||
| PCT/EP2015/069370 WO2016030335A1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002328A true MX2017002328A (es) | 2017-05-22 |
| MX369649B MX369649B (es) | 2019-11-15 |
Family
ID=54014804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002328A MX369649B (es) | 2014-08-25 | 2015-08-24 | Analogos de dioxolano de uridina para el tratamiento del cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (es) |
| EP (2) | EP3572410B1 (es) |
| JP (2) | JP6663424B2 (es) |
| KR (2) | KR102396905B1 (es) |
| CN (4) | CN110790789B (es) |
| AU (2) | AU2015308988C1 (es) |
| BR (1) | BR112017003898B1 (es) |
| CA (2) | CA2956251C (es) |
| CY (1) | CY1122945T1 (es) |
| DK (2) | DK3572410T3 (es) |
| EA (2) | EA031106B1 (es) |
| ES (2) | ES2927212T3 (es) |
| HR (1) | HRP20201023T1 (es) |
| HU (2) | HUE050705T2 (es) |
| IL (2) | IL250344B (es) |
| MX (1) | MX369649B (es) |
| MY (2) | MY188089A (es) |
| NZ (2) | NZ729118A (es) |
| PH (2) | PH12017500184A1 (es) |
| PL (2) | PL3572410T3 (es) |
| PT (2) | PT3186244T (es) |
| SG (3) | SG10201911558UA (es) |
| WO (1) | WO2016030335A1 (es) |
| ZA (1) | ZA201802864B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201023T1 (hr) * | 2014-08-25 | 2020-10-16 | Medivir Aktiebolag | Dioksilan analozi uridina za liječenje raka |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| MY196772A (en) * | 2015-12-11 | 2023-05-03 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| ES2987989T3 (es) * | 2016-03-02 | 2024-11-18 | Medivir Ab | Terapia combinada con sorafenib o regorafenib y un profármaco de fosforamidato de troxacitabina |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| JP2020500853A (ja) * | 2016-11-18 | 2020-01-16 | ネウロビベ プハルマセウトイカル エービー | ミトコンドリアのプロトンイオノフォアの肝臓プロドラッグ |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| JP7337539B2 (ja) | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| HUE065972T2 (hu) * | 2019-02-18 | 2024-06-28 | Medivir Ab | Gyógyszerkombináció a májrák kezelésére szolgáló eljárásban történõ alkalmazásra |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113402546A (zh) * | 2020-03-17 | 2021-09-17 | 浙江四维医药科技有限公司 | 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法 |
| CA3174940A1 (en) * | 2020-04-15 | 2021-10-21 | Fredrik Oberg | Miv-818/lenvatinib combination therapy for liver cancer |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
| WO2025155547A1 (en) * | 2024-01-17 | 2025-07-24 | University Of Georgia Research Foundation, Inc. | An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| HUP0301363A2 (hu) * | 2000-10-13 | 2005-12-28 | Shire Biochem Inc. | Javított intercelluláris bejuttathatóságú dioxolán analógok |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| US20100266674A1 (en) * | 2006-09-01 | 2010-10-21 | University Of Georgia Research Foundation, Inc. | L-oddc prodrugs for cancer |
| PL216525B1 (pl) * | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| EP3074411A2 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of liver cancer |
| HRP20201023T1 (hr) * | 2014-08-25 | 2020-10-16 | Medivir Aktiebolag | Dioksilan analozi uridina za liječenje raka |
-
2015
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184A1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002328A (es) | Analogos de dioxolano de uridina para el tratamiento del cancer. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| JOP20190194B1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EA201892147A1 (ru) | Бициклические соединения | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| PH12016501941A1 (en) | Use of heterocyclic compounds for controlling nematodes | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| ECSP17010238A (es) | Compuestos novedosos de pirimidina sustituidos | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| MX378601B (es) | Derivados de dipicolilamina y sus usos farmaceuticos. | |
| MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
| MX2019008375A (es) | Tiobenzoimidazol como fungicidas. | |
| EA201792502A1 (ru) | Кабазитаксел и его применение для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |